Similarly, in BRAF-mutant melanoma models treated with BRAF/MEK inhibitors, the next-generation pan-BET inhibitor PLX51107 suppresses adaptive receptor tyrosine kinase upregulation in response to targeted therapy. Here, BRAF is linked to melanoma.